Adagio Therapeutics, Inc.(NASDAQ : ADGI)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Commercial Services » Miscellaneous Commercial Services
|CRL||Charles River Laboratories International, Inc.||-1.81%||318.78||4.5%||$134.57m|
|FLT||FLEETCOR Technologies, Inc.||-2.81%||220.06||3.7%||$111.50m|
|TAX||Liberty Tax, Inc. Class A||2.43%||47.26||2.5%||$64.43m|
|BAH||Booz Allen Hamilton Holding Corp.||-0.42%||85.01||2.1%||$55.44m|
|FOUR||Shift4 Payments, Inc.||-0.78%||46.07||0.0%||$53.39m|
|BFAM||Bright Horizons Family Solutions, Inc.||0.17%||126.49||1.4%||$48.46m|
|PAGS||PagSeguro Digital Ltd.||-0.10%||20.72||0.0%||$47.74m|
|SYNH||Syneos Health, Inc.||-0.82%||85.53||0.0%||$41.66m|
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.